Distribution of tumor subtype by hormone receptor and HER2-expression was HR-positive/HER2-negative in 43 (26%) patients, HR-positive/HER2-positive in 41 (24%) patients, HR-negative/HER2-positive in 23 (14%) patients, and triple-negative in 60 (36%) patients. This evidence concerns the gene NR4A1 and neoplasm.